Clinical trials: Alzheimer Disease 4
Alzheimer's Disease
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes…
- Trial name
- ENVISION (NCT05310071)
- Testing
- Aducanumab
- Where
- 265 sites in United States, Australia and 14 more
- Volunteers
- 1,027 people
- Sponsor
- Biogen
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Healthy, Adult
Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
Primary: To evaluate the pharmacologic effect of single doses of SAM-531 on sleep EEG in healthy subjects.
- Trial name
- NCT00519298
- Testing
- SAM-531, Donepezil
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD).
- Trial name
- NCT00602680
- Testing
- SSR180711C, donepezil
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Sanofi
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00676143
- Testing
- bapineuzumab
- Where
- 288 sites in United States, Argentina and 22 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer's Disease
AZD3293 Thorough QT Study in Healthy Male Volunteers
A thorough QT study of AZD3293
- Trial name
- AZD3293TQT (NCT02040987)
- Testing
- AZD3293, Moxifloxacin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Mild to Moderate Alzheimer's Disease
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ROBIN (NCT01039701)
- Testing
- AZD1446
- Where
- 12 sites in Czechia, Hungary and 1 more
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD).
- Trial name
- NCT07838155
- Testing
- Donanemab
- Where
- 12 sites in India
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain.
- Trial name
- NCT00040443
- Testing
- CX516
- Where
- 8 sites in United States
- Volunteers
- 175 people
- Sponsor
- RespireRx
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy Volunteers
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.
- Trial name
- NCT04208152
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Mild Cognitive Impairment (MCI), Alzheimer Disease
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT05108922
- Testing
- Donanemab, Aducanumab
- Where
- 31 sites in United States
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00667810
- Testing
- bapineuzumab
- Where
- 346 sites in United States, Argentina and 24 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Alzheimer Disease
Single Dose Study of ALZ-801 Prototype Tablets
Phase 1, single-center, open-label, non-randomized, sequential single dose 4-period study in 12 healthy subjects to assess the pharmacokinetics of ALZ-801, tramiprosate and the primary metabolite of tramiprosate, NRM5074, from…
- Trial name
- NCT04585347
- Testing
- ALZ-801 170 mg Fasting, ALZ-801 205 mg Fasting, ALZ-801 205 mg After Food
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alzheon Inc.
Alzheimer's Disease, Healthy
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
The purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the Phase 2 study.
- Trial name
- NCT00901498
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb